Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas (scientific article)

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

Q24646237

Targeting the mTOR signaling network for cancer therapy

Q24658334

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

Q27851446

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Q27851451

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Q27851457

TOR signaling in growth and metabolism

Q27860757

High frequency of mutations of the PIK3CA gene in human cancers

Q28131776

PTEN1 is frequently mutated in primary endometrial carcinomas

Q28250937

PI3K pathway alterations in cancer: variations on a theme

Q29615530

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Q29617685

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Q29618031

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Q29618117

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Q29618608

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

Q33564297

The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma

Q34001234

Global cancer statistics in the year 2000.

Q34571897

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

Q35172203

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability

Q35275603

4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors

Q35778060

PTEN-deficient cancers depend on PIK3CB.

Q36861839

Novel molecular profiles of endometrial cancer-new light through old windows.

Q37025301

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

Q37036297

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

Q37140110

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts.

Q37177892

The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas

Q37269747

Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis

Q37360125

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

Q37376100

Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations

Q37382669

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.

Q37396608

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

Q37765246

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models

Q39706127

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

Q39827794

PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation

Q39933516

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma

Q40345165

Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations

Q43041602

Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination

Q43177478

RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.

Q51761211

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

Q51803667

PTEN mutation spectrum in breast cancers and breast hyperplasia.

Q53300858

K-ras activation in premalignant and malignant epithelial lesions of the human uterus

Q68003898

PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas

Q74509230

Endometrial cancer

Q81833884

Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway

Q82452891

Everolimus

Q83011817

P275

Creative Commons Attribution 4.0 International

copyrighted

issue

language of work or name

English

Q1860

P921

main subject

dactolisib

Q4835503

P304

page(s)

e37431

P577

publication date

2012-05-25

P1433

published in

PLOS One

Q564954

P1476

title

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas

P478

volume

Reverse relations

cites work (P2860)

Q36790208	A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies
Q27852958	A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.
Q33557916	Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
Q37554263	Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
Q38868621	Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Q54375657	Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Q38812141	Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies
Q28073246	Chemoresistance and targeted therapies in ovarian and endometrial cancers
Q34508976	Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
Q50981985	Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Q37016570	Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models
Q38598081	Emerging strategies for targeting PI3K in gynecologic cancer
Q39026766	Endometrial Carcinoma: Specific Targeted Pathways.
Q36857470	Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.
Q38258712	Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies
Q33598001	Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer
Q39098938	HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
Q37082531	In-depth molecular profiling of the biphasic components of uterine carcinosarcomas
Q54379484	Insulin exerts direct effects on carcinogenic transformation of human endometrial organotypic cultures.
Q34299944	Mammalian target of rapamycin complex 1 and cyclooxygenase 2 pathways cooperatively exacerbate endometrial cancer
Q52747351	MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR.
Q54377413	Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.
Q38067440	Molecular pathology of endometrial carcinoma
Q35940829	Molecular staging of gynecological cancer: What is the future?
Q36684551	New candidate therapeutic agents for endometrial cancer: potential for clinical practice (review).
Q36980561	PI3K pathway dependencies in endometrioid endometrial cancer cell lines
Q38882236	PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer.
Q34016861	PTEN-deficient tumors depend on AKT2 for maintenance and survival
Q37006856	Personalized care in uterine cancer.
Q90654533	Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer
Q38185940	Prognostic biomarkers in endometrial and ovarian carcinoma
Q38778227	Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer.
Q37301884	Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging
Q37381834	TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers
Q57169683	Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late
Q39454208	Targeted endometrial cancer therapy as a future prospect
Q55220517	The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies.
Q51767323	The Yokohama system for reporting directly sampled endometrial cytology: The quest to develop a standardized terminology.
Q38890954	The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition.
Q41582917	The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells
Q27852764	Therapeutic targeting of cancers with loss of PTEN function
Q26779980	Tumor progression, metastasis, and modulators of epithelial-mesenchymal transition in endometrioid endometrial carcinoma: an update
Q37649634	mTOR pathway in colorectal cancer: an update

P819	ADS bibcode	2012PLoSO...737431S
P356	DOI	10.1371/JOURNAL.PONE.0037431
P932	PMC publication ID	3360787
P698	PubMed publication ID	22662154
P5875	ResearchGate publication ID	225098191